Alkermes Inc., of Cambridge, Mass., appointed Joseph Anisko vice president of quality.

Althea Technologies Inc., of San Diego, added David Vandertie as vice president and chief financial officer and Joseph Monforte as vice president and chief scientific officer.

Amarin Corp. plc, of London, appointed Margie Nemcik-Cruz vice president, regulatory affairs of Amarin Pharmaceuticals Inc.

Ariad Pharmaceuticals Inc., of Cambridge, Mass., appointed Camille Bedrosian vice president and chief medical officer.

Aton Pharma Inc., of Tarrytown, N.Y., promoted Judy Chiao to vice president, oncology clinical research and development.

Auilix Biopharma Inc., of Berkeley, Calif., added Mark Ptashne to its scientific advisory board.

Barrier Therapeutics Inc., of Princeton, N.J., appointed Anne VanLent executive vice president and chief financial officer.

BioStratum Inc., of Research Triangle Park, N.C., appointed Claus Kühl vice chairman of its board and Robert Schotzinger president and chief operating officer. Also, Gary Gordon was promoted to vice president of finance and business development and chief financial officer.

Biovu, of Nottingham, UK, appointed Carole Kenyon chief operating officer.

Chiron Corp., of Emeryville, Calif., appointed Denise O'Leary to its board.

Cyclacel Ltd., of Dundee, UK, appointed John Banham nonexecutive chairman.

Cytochroma Inc., of Markham, Ontario, added Pierre Chambon, John Falck, David Feldman and Reuben Lotan to its scientific advisory board.

De Novo Ventures, of Menlo Park, Calif., added Jay Watkins as managing director.

DelSite Biotechnologies Inc., of Irving, Texas, added Leigh Thompson to its scientific advisory board.

Digene Corp., of Gaithersburg, Md., elected Cynthia Sullivan to its board.

D-Pharm Ltd., of Rehovot, Israel, appointed Brian Berman chief financial officer.

Generex Biotechnology Corp., of Toronto, appointed Peter Levitch to its board.

Genesis Research and Development Corp. Ltd., of Auckland, New Zealand, formed a strategic development unit, consisting of Andrew Shenk and Doug Williams.

GenOdyssee SA, of Paris, appointed Jean-Marc Giry vice president of strategic planning, Philippe Remes vice president of investor relations and David Briscoe vice president of business development. All were appointed to the board.

Genome Express, of Grenoble, France, appointed Francois Pons as director of business development.

GenVec Inc., of Gaithersburg, Md., elected Barbara Hackman Franklin to its board.

GlycoGenesys Inc., of Boston, added Michael Hanson to its board and William O'Neill Fabbri as general counsel.

Gryphon Sciences, of South San Francisco, appointed Patrick Zenner to its board.

Illumina Inc., of San Diego, appointed Susan Eddins head of worldwide marketing.

InterMune Inc., of Brisbane, Calif., named Sharon Surrey-Barbari chief financial officer and senior vice president of finance and administration.

Lorus Therapeutics Inc., of Toronto, appointed Mace Rothenberg external medical adviser.

Microbia Inc., of Cambridge, Mass., appointed Mark Currie vice president, research and development.

NeoGenomics Inc., of Naples, Fla., added Phillip Roland and David Fries to its scientific advisory board. Also, it added Peter Kohn as director of its clinical genetics and research laboratory.

Neose Technologies Inc., of Horsham, Pa., appointed Joseph Villafranca senior vice president, pharmaceutical development and operations. Also, it added Patrick Gage to its board.